What is the recommended nasal spray treatment for an adult patient with acute sinusitis?

Recommended Nasal Spray Treatment for Acute Sinusitis in Adults

For adults with acute post-viral sinusitis, use mometasone furoate nasal spray (MFNS) 200 mcg (2 sprays) in each nostril twice daily for 15 days, which provides superior symptom relief compared to both antibiotics and placebo. 1

Primary Treatment Recommendation

Mometasone furoate (Nasonex) is the preferred intranasal corticosteroid based on the highest quality evidence from the European Position Paper on Rhinosinusitis 2020, which demonstrates:

• 200 mcg twice daily (2 sprays per nostril, twice daily) for 15 days produces significantly greater symptom improvement than amoxicillin or placebo 1, 2
• Significantly increases minimal-symptom days (62.69% vs 50.33% for placebo, p<0.0001) 3
• Reduces time to first minimal-symptom day to 8.5 days versus 11 days for placebo (p=0.0085) 3
• Particularly effective for congestion, headache, and facial pain symptoms 1, 4

Alternative Intranasal Corticosteroid Options

If mometasone is unavailable, fluticasone propionate 200 mcg daily (2 sprays per nostril once daily) for 14-15 days is an acceptable alternative:

• FDA-approved dosing is 2 sprays (50 mcg each) per nostril once daily in adults 5
• Onset of symptom relief occurs within 12 hours, with maximum effect in several days 5
• Demonstrated efficacy in reducing total nasal symptom scores compared to placebo 5

Fluticasone furoate 110 mcg twice daily also shows efficacy but with smaller effect sizes than mometasone 1

Critical Dosing Details

For mometasone:

• Standard dose: 200 mcg twice daily (2 sprays per nostril, twice daily) 1
• Lower dose of 200 mcg once daily shows benefit but is less effective than twice-daily dosing 1, 2
• Treatment duration: minimum 15 days 1, 6

For fluticasone propionate:

• Standard dose: 200 mcg once daily (2 sprays per nostril once daily) 5
• Alternative: 100 mcg twice daily (1 spray per nostril twice daily) 5
• Treatment duration: 14-15 days minimum 6

Important Clinical Context

Intranasal corticosteroids should only be prescribed when symptom reduction is necessary, as acute post-viral rhinosinusitis is self-limiting in most cases 1, 6. The European Position Paper on Rhinosinusitis 2020 notes:

• The effect size is modest (number needed to treat = 14) 7
• No significant improvement in quality of life measures (SNOT-20) has been demonstrated 1
• Evidence quality is moderate due to heterogeneity 1

When NOT to Use Intranasal Corticosteroids Alone

Do not use intranasal corticosteroids as monotherapy if:

• Symptoms suggest acute bacterial rhinosinusitis (severe symptoms, high fever >101°F, worsening after initial improvement) 8, 9
• Red flag symptoms are present: periorbital edema, severe unilateral headache, visual changes, neurological symptoms, or signs of sepsis 6
• Symptoms have persisted beyond 12 weeks (suggests chronic rhinosinusitis requiring different management) 10

Adjunctive Symptomatic Treatments

Combine intranasal corticosteroids with:

• Analgesics (acetaminophen or NSAIDs) for facial pain and headache 8, 7
• Saline nasal irrigation (buffered hypertonic 3-5% saline preferred) for symptom relief and mucus clearance 8, 7

Avoid or use cautiously:

• Oral antihistamines (no proven benefit unless concurrent allergic rhinitis) 8, 6
• Topical decongestants beyond 3-5 days (risk of rhinitis medicamentosa/rebound congestion) 8, 6
• Oral corticosteroids (no demonstrated benefit in post-viral rhinosinusitis) 7, 6

Critical Administration Technique

Use the contralateral hand technique to minimize epistaxis risk:

• Hold the spray bottle in the opposite hand relative to the nostril being treated 11
• Aim slightly away from the nasal septum 11
• Do not close the opposite nostril during administration 11
• This technique reduces epistaxis risk by four times 11

Antibiotic Considerations

Antibiotics are NOT indicated for post-viral acute rhinosinusitis:

• Amoxicillin shows no benefit over placebo in post-viral rhinosinusitis 1, 12, 6
• Mometasone 200 mcg twice daily is superior to amoxicillin 500 mg three times daily for symptom relief 1, 2
• Colored nasal discharge does NOT indicate bacterial infection and does not justify antibiotics 6

Reserve antibiotics for acute bacterial rhinosinusitis meeting specific criteria: severe symptoms at onset, worsening after initial improvement, or persistent symptoms >10 days without improvement 8, 9

Common Pitfalls to Avoid

• Stopping treatment prematurely: Benefit requires 14-15 days minimum; many patients discontinue too early 6
• Assuming colored discharge means bacterial infection: This reflects neutrophil presence, not bacteria, and does NOT justify antibiotics 6
• Using topical decongestants beyond 3-5 days: This causes rebound congestion 6
• Adding antibiotics unnecessarily: They are completely ineffective for post-viral rhinosinusitis and contribute to antimicrobial resistance 6

Safety Profile

Intranasal corticosteroids are safe for the recommended treatment duration:

• Most common adverse events: headache, epistaxis (nosebleeds), pharyngitis, nasal itching—all mild to moderate 1, 11
• No hypothalamic-pituitary-adrenal axis suppression at recommended doses 11
• No rebound congestion (unlike topical decongestants) 11
• Safe for long-term use when clinically indicated 11

Patient Counseling Points

• Onset of action is delayed approximately 12 hours, with maximal efficacy in days to weeks 11, 5
• Regular daily use is essential—not as-needed dosing 11
• Continue for the full 14-15 day course even if symptoms improve earlier 6
• Most patients experience self-resolution within 10-14 days regardless of treatment 6